Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016–2017 season in Beijing, China

17Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Background: Since 2007, trivalent inactivated influenza vaccine (TIV) has been provided free-of-charge to primary, middle school and high school students in Beijing. However, there have been few school-based studies on influenza vaccine effectiveness (VE). In this report, we estimated influenza VE against laboratory-confirmed influenza illness among school children in Beijing, China during the 2016–2017 influenza season. Methods: The VE of 2016–2017 TIV against laboratory-confirmed influenza virus infection among school-age children was assessed through a case–control design. Conditional logistic regression was conducted on matched case–control sets to estimate VE. The effect of prior vaccination on current VE was also examined. Results: All 176 samples tested positive for influenza A virus with the positive rate of 55.5%. The average coverage rate of 2016–2017 TIV among students across the 37 schools was 30.6%. The fully adjusted VE of 2016–2017 TIV against laboratory-confirmed influenza was 69% (95% CI: 51 to 81): 60% (95% CI: −15 to 86) for influenza A(H1N1)pdm09 and 73% (95% CI: 52 to 84) for influenza A(H3N2). The overall VE for receipt of 2015–2016 vaccination only, 2016–2017 vaccination only, and vaccinations in both seasons was 46% (95% CI: −5 to 72), 77% (95% CI: 58 to 87), and 57% (95%CI: 17 to 78), respectively. Conclusions: Our study during school outbreaks found that VE of 2016–2017 TIV was moderate against influenza A(H3N2) as well as A(H1N1)pdm09 viruses.

Cite

CITATION STYLE

APA

Zhang, L., van der Hoek, W., Krafft, T., Pilot, E., Asten, L. van, Lin, G., … Wang, Q. (2020). Influenza vaccine effectiveness estimates against influenza A(H3N2) and A(H1N1) pdm09 among children during school-based outbreaks in the 2016–2017 season in Beijing, China. Human Vaccines and Immunotherapeutics, 16(4), 816–822. https://doi.org/10.1080/21645515.2019.1677438

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free